
ResMed (RMD) | Financial Analysis & Statements
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Jun 2025Income Metrics
Revenue
1.3B
Gross Profit
820.1M
60.84%
Operating Income
456.6M
33.87%
Net Income
379.7M
28.17%
Balance Sheet Metrics
Total Assets
8.2B
Total Liabilities
2.2B
Shareholders Equity
6.0B
Debt to Equity
0.37
Cash Flow Metrics
Operating Cash Flow
441.4M
Free Cash Flow
505.0M
Revenue & Profitability Trend
ResMed Income Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Revenue | 5.1B | 4.7B | 4.2B | 3.6B | 3.2B |
Cost of Goods Sold | 2.1B | 2.0B | 1.9B | 1.6B | 1.4B |
Gross Profit | 3.1B | 2.7B | 2.4B | 2.0B | 1.8B |
Gross Margin % | 59.4% | 56.7% | 55.8% | 56.6% | 57.5% |
Operating Expenses | |||||
Research & Development | 331.3M | 307.5M | 287.6M | 253.6M | 225.3M |
Selling, General & Administrative | 991.0M | 917.1M | 874.0M | 737.5M | 670.4M |
Other Operating Expenses | - | - | - | - | - |
Total Operating Expenses | 1.3B | 1.2B | 1.2B | 991.1M | 895.7M |
Operating Income | 1.7B | 1.4B | 1.2B | 1.0B | 912.4M |
Operating Margin % | 32.8% | 29.5% | 27.3% | 28.0% | 28.5% |
Non-Operating Items | |||||
Interest Income | - | - | - | - | 362.0K |
Interest Expense | - | 45.7M | 47.4M | 22.3M | 24.0M |
Other Non-Operating Income | -13.9M | -73.6M | -3.0M | -19.4M | -5.1M |
Pre-tax Income | 1.7B | 1.3B | 1.1B | 960.5M | 883.7M |
Income Tax | 276.8M | 243.8M | 204.1M | 181.0M | 409.2M |
Effective Tax Rate % | 16.5% | 19.3% | 18.5% | 18.8% | 46.3% |
Net Income | 1.4B | 1.0B | 897.6M | 779.4M | 474.5M |
Net Margin % | 27.2% | 21.8% | 21.3% | 21.8% | 14.8% |
Key Metrics | |||||
EBITDA | 1.9B | 1.6B | 1.3B | 1.2B | 1.1B |
EPS (Basic) | - | $6.94 | $6.12 | $5.34 | $3.27 |
EPS (Diluted) | - | $6.92 | $6.09 | $5.30 | $3.24 |
Basic Shares Outstanding | - | 147021000 | 146765000 | 146066000 | 145313000 |
Diluted Shares Outstanding | - | 147021000 | 146765000 | 146066000 | 145313000 |
Income Statement Trend
ResMed Balance Sheet From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Assets | |||||
Current Assets | |||||
Cash & Equivalents | 1.2B | 238.4M | 227.9M | 273.7M | 295.3M |
Short-term Investments | - | - | - | - | - |
Accounts Receivable | 939.5M | 837.3M | 704.9M | 576.0M | 614.3M |
Inventory | 927.7M | 822.2M | 998.0M | 743.9M | 457.0M |
Other Current Assets | 164.5M | 180.0M | 179.9M | 131.3M | 208.2M |
Total Current Assets | 3.5B | 2.4B | 2.4B | 1.9B | 1.6B |
Non-Current Assets | |||||
Property, Plant & Equipment | 288.6M | 278.5M | 243.7M | 237.8M | 239.2M |
Goodwill | 6.6B | 6.2B | 6.1B | 4.2B | 4.2B |
Intangible Assets | 464.9M | 485.9M | 552.3M | 345.9M | 392.6M |
Long-term Investments | - | - | - | - | - |
Other Non-Current Assets | 439.0M | 487.6M | 395.4M | 251.5M | 240.8M |
Total Non-Current Assets | 4.7B | 4.5B | 4.4B | 3.2B | 3.2B |
Total Assets | 8.2B | 6.9B | 6.8B | 5.1B | 4.7B |
Liabilities | |||||
Current Liabilities | |||||
Accounts Payable | 278.2M | 237.7M | 150.8M | 159.2M | 138.0M |
Short-term Debt | 40.4M | 35.2M | 31.8M | 31.8M | 35.6M |
Current Portion of Long-term Debt | - | - | - | - | - |
Other Current Liabilities | 2.7M | 4.7M | 9.6M | 1.9M | - |
Total Current Liabilities | 1.0B | 910.7M | 758.5M | 689.3M | 911.8M |
Non-Current Liabilities | |||||
Long-term Debt | 811.4M | 838.8M | 1.5B | 885.8M | 758.1M |
Deferred Tax Liabilities | 77.7M | 79.3M | 90.6M | 9.7M | 11.3M |
Other Non-Current Liabilities | 141.5M | 42.3M | 68.2M | 6.0M | 6.8M |
Total Non-Current Liabilities | 1.2B | 1.1B | 1.9B | 1.0B | 930.7M |
Total Liabilities | 2.2B | 2.0B | 2.6B | 1.7B | 1.8B |
Equity | |||||
Common Stock | 761.0K | 588.0K | 588.0K | 586.0K | 583.0K |
Retained Earnings | 6.1B | 5.0B | 4.3B | 3.6B | 3.1B |
Treasury Stock | 2.1B | 1.8B | 1.6B | 1.6B | 1.6B |
Other Equity | - | - | - | - | - |
Total Shareholders Equity | 6.0B | 4.9B | 4.1B | 3.4B | 2.9B |
Key Metrics | |||||
Total Debt | 851.8M | 873.9M | 1.6B | 917.6M | 793.7M |
Working Capital | 2.5B | 1.4B | 1.6B | 1.2B | 663.0M |
Balance Sheet Composition
ResMed Cash Flow Statement From 2021 to 2025
Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
---|---|---|---|---|---|
Operating Activities | |||||
Net Income | 1.4B | 1.0B | 897.6M | 779.4M | 474.5M |
Depreciation & Amortization | 235.8M | 216.2M | 197.6M | 193.8M | 191.5M |
Stock-Based Compensation | 91.7M | 80.2M | 71.1M | 65.3M | 63.9M |
Working Capital Changes | -156.8M | 37.9M | -355.3M | -540.0M | 59.6M |
Operating Cash Flow | 1.6B | 1.4B | 799.9M | 498.6M | 798.2M |
Investing Activities | |||||
Capital Expenditures | -89.9M | -99.5M | -119.7M | -134.8M | -102.7M |
Acquisitions | -139.2M | -133.5M | -1.0B | -42.8M | -39.1M |
Investment Purchases | -6.4M | -22.5M | -32.2M | -37.9M | -21.8M |
Investment Sales | 46.3M | 1.0M | 19.1M | 6.8M | 19.2M |
Investing Cash Flow | -189.3M | -254.4M | -1.1B | -208.7M | -144.3M |
Financing Activities | |||||
Share Repurchases | -300.0M | -150.0M | 0 | 0 | 0 |
Dividends Paid | -310.9M | -282.3M | -258.3M | -245.3M | -226.7M |
Debt Issuance | 0 | 105.0M | 1.1B | 288.0M | 90.0M |
Debt Repayment | -40.0M | -835.0M | -405.0M | -166.0M | -612.0M |
Financing Cash Flow | -606.3M | -1.1B | 422.9M | -128.4M | -764.6M |
Free Cash Flow | 1.7B | 1.3B | 559.3M | 195.1M | 619.9M |
Net Change in Cash | 775.8M | 14.8M | 77.2M | 161.5M | -110.8M |
Cash Flow Trend
ResMed Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
29.93
Forward P/E
27.69
Price to Book
6.99
Price to Sales
8.11
PEG Ratio
27.69
Profitability Ratios
Profit Margin
27.22%
Operating Margin
33.87%
Return on Equity
25.86%
Return on Assets
14.02%
Financial Health
Current Ratio
3.44
Debt to Equity
14.27
Beta
0.77
Per Share Data
EPS (TTM)
$9.52
Book Value per Share
$40.77
Revenue per Share
$35.08
Peer Financial Comparison
Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
---|---|---|---|---|---|---|
rmd | 41.7B | 29.93 | 6.99 | 25.86% | 27.22% | 14.27 |
Intuitive Surgical | 172.2B | 67.08 | 9.65 | 16.04% | 28.51% | 0.00 |
Becton, Dickinson | 56.3B | 35.89 | 2.21 | 6.18% | 7.41% | 75.93 |
Alcon | 45.8B | 40.84 | 2.07 | 5.23% | 11.28% | 23.63 |
West Pharmaceutical | 17.7B | 36.91 | 6.04 | 17.72% | 16.48% | 10.52 |
Hologic | 15.1B | 28.14 | 3.11 | 11.38% | 13.79% | 52.09 |
Financial data is updated regularly. All figures are in the company's reporting currency.